Literature DB >> 25399875

Treatment of acute optic neuritis and vision complaints in multiple sclerosis.

Ruben Torres-Torres1, Bernardo F Sanchez-Dalmau.   

Abstract

OPINION STATEMENT: Multiple sclerosis is an autoimmune demyelinating disorder of the nervous system, in which almost all patients develop some degree of visual impairment during the disease. Optic neuritis is the most common and known visual affection and may be the initial clinical disease manifestation, but visual complaints can have a wide variety of presentations and some of them can lead to clinical confusion. Most symptoms are the result of acute injury and subsequent axonal loss in the afferent and efferent visual pathway, but others may be consequences of treatments. Currently, we can tell the functional and anatomical damage caused by multiple sclerosis by visual function test, measurement of eye movements, electrophysiological testing, optical coherence tomography, and magnetic resonance imaging. The purpose of this review is to describe the afferent and efferent visual symptoms associated with multiple sclerosis or multiple sclerosis treatment, and review the current and future therapeutic options available for them.

Entities:  

Year:  2015        PMID: 25399875     DOI: 10.1007/s11940-014-0328-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  42 in total

Review 1.  Intravenous immunoglobulin: adverse effects and safe administration.

Authors:  Hedi Orbach; Uriel Katz; Yaniv Sherer; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Uhthoff's syndrome.

Authors:  G D Perkin; F C Rose
Journal:  Br J Ophthalmol       Date:  1976-01       Impact factor: 4.638

3.  Clinical profile of simultaneous bilateral optic neuritis in adults.

Authors:  J de la Cruz; M J Kupersmith
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

4.  Interferon-associated combined branch retinal artery and central retinal vein obstruction.

Authors:  Juan E Rubio; Steve Charles
Journal:  Retina       Date:  2003-08       Impact factor: 4.256

5.  Paroxysmal convergence spasm in multiple sclerosis.

Authors:  T Postert; U McMonagle; T Büttner; D Pöhlau; S Meves; H Przuntek
Journal:  Acta Neurol Scand       Date:  1996-07       Impact factor: 3.209

Review 6.  Visual issues in multiple sclerosis.

Authors:  Courtney E Francis
Journal:  Phys Med Rehabil Clin N Am       Date:  2013-07-25       Impact factor: 1.784

7.  Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients.

Authors:  I Bolaños; D Lozano; C Cantú
Journal:  Acta Neurol Scand       Date:  2004-09       Impact factor: 3.209

Review 8.  Internuclear ophthalmoplegia: pathophysiology and diagnosis.

Authors:  D S Zee
Journal:  Baillieres Clin Neurol       Date:  1992-08

9.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Authors:  G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H P Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K M Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi
Journal:  Lancet       Date:  2009-10-06       Impact factor: 79.321

10.  Eye disorders in patients with multiple sclerosis: natural history and management.

Authors:  Jennifer Graves; Laura J Balcer
Journal:  Clin Ophthalmol       Date:  2010-12-06
View more
  2 in total

1.  Acute optic neuritis in multiple sclerosis.

Authors:  Brian Garrett; Adam A Dmytriw; Charles Maxner
Journal:  CMAJ       Date:  2015-11-23       Impact factor: 8.262

2.  Diffusion MRI quantifies early axonal loss in the presence of nerve swelling.

Authors:  Tsen-Hsuan Lin; Chia-Wen Chiang; Carlos J Perez-Torres; Peng Sun; Michael Wallendorf; Robert E Schmidt; Anne H Cross; Sheng-Kwei Song
Journal:  J Neuroinflammation       Date:  2017-04-07       Impact factor: 8.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.